LeMaitre Vascular (NASDAQ:LMAT) Stock Price Down 3.5% - Time to Sell?

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report)'s share price fell 3.5% during trading on Thursday . The stock traded as low as $81.19 and last traded at $81.56. 58,778 shares were traded during mid-day trading, a decline of 65% from the average session volume of 169,966 shares. The stock had previously closed at $84.54.

LeMaitre Vascular Stock Performance

The firm's fifty day moving average is $83.66 and its 200-day moving average is $88.69. The company has a current ratio of 16.49, a quick ratio of 13.83 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $1.87 billion, a PE ratio of 41.70, a price-to-earnings-growth ratio of 2.18 and a beta of 0.83.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The company had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a net margin of 19.96% and a return on equity of 13.53%. During the same quarter in the prior year, the business earned $0.44 earnings per share. LeMaitre Vascular's revenue was up 12.0% on a year-over-year basis. As a group, research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date was Thursday, May 15th. LeMaitre Vascular's payout ratio is 40.40%.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 4,399 shares of LeMaitre Vascular stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $85.10, for a total value of $374,354.90. Following the completion of the transaction, the chief executive officer now directly owns 1,827,003 shares of the company's stock, valued at $155,477,955.30. The trade was a 0.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 100,000 shares of company stock worth $8,556,857 over the last ninety days. Corporate insiders own 9.50% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in LMAT. Flputnam Investment Management Co. grew its stake in LeMaitre Vascular by 3.6% during the 4th quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier's stock worth $269,000 after purchasing an additional 102 shares in the last quarter. Norden Group LLC raised its position in LeMaitre Vascular by 4.5% in the 4th quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier's stock valued at $218,000 after purchasing an additional 103 shares in the last quarter. Blue Barn Wealth LLC boosted its stake in shares of LeMaitre Vascular by 4.4% in the 4th quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier's stock valued at $229,000 after buying an additional 104 shares during the period. CBIZ Investment Advisory Services LLC grew its position in shares of LeMaitre Vascular by 38.5% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 117 shares in the last quarter. Finally, Sanctuary Advisors LLC increased its stake in shares of LeMaitre Vascular by 6.0% during the fourth quarter. Sanctuary Advisors LLC now owns 2,065 shares of the medical instruments supplier's stock worth $207,000 after buying an additional 117 shares during the period. Hedge funds and other institutional investors own 84.64% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.